Terms: = Ovarian cancer AND SFRP4, Q6FHJ7, 6424, ENSG00000106483, frpHE, MGC26498, FRPHE, FRP-4 AND Treatment
8 results:
1. Short peptide domains of the Wnt inhibitor sfrp4 target ovarian cancer stem cells by neutralizing the Wnt β-catenin pathway, disrupting the interaction between β-catenin and CD24 and suppressing autophagy.
Sundaram SM; Varier L; Fathima KZ; Dharmarajan A; Warrier S
Life Sci; 2023 Mar; 316():121384. PubMed ID: 36646377
[TBL] [Abstract] [Full Text] [Related]
2. Senotherapy Protects against Cisplatin-Induced ovarian Injury by Removing Senescent Cells and Alleviating DNA Damage.
Du D; Tang X; Li Y; Gao Y; Chen R; Chen Q; Wen J; Wu T; Zhang Y; Lu H; Zhang J; Wang S
Oxid Med Cell Longev; 2022; 2022():9144644. PubMed ID: 35693700
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and sfrp4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study.
Turan H; Vitale SG; Kahramanoglu I; Della Corte L; Giampaolino P; Azemi A; Durmus S; Sal V; Tokgozoglu N; Bese T; Arvas M; Demirkiran F; Gelisgen R; Ilvan S; Uzun H
Arch Gynecol Obstet; 2022 Dec; 306(6):2105-2114. PubMed ID: 35461390
[TBL] [Abstract] [Full Text] [Related]
4. Epigenetic demethylation of sFRPs, with emphasis on sfrp4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells.
Deshmukh A; Arfuso F; Newsholme P; Dharmarajan A
Int J Biochem Cell Biol; 2019 Apr; 109():23-32. PubMed ID: 30710752
[TBL] [Abstract] [Full Text] [Related]
5. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010.
Nagase S; Ohta T; Takahashi F; Enomoto T;
J Obstet Gynaecol Res; 2019 Feb; 45(2):289-298. PubMed ID: 30426591
[TBL] [Abstract] [Full Text] [Related]
6. Secreted Frizzled-related protein 4 (sfrp4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines.
Deshmukh A; Kumar S; Arfuso F; Newsholme P; Dharmarajan A
Sci Rep; 2017 May; 7(1):2256. PubMed ID: 28536422
[TBL] [Abstract] [Full Text] [Related]
7. The Wnt gatekeeper sfrp4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
[TBL] [Abstract] [Full Text] [Related]
8. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.
Schlumbrecht MP; Xie SS; Shipley GL; Urbauer DL; Broaddus RR
Mod Pathol; 2011 Mar; 24(3):453-62. PubMed ID: 21102415
[TBL] [Abstract] [Full Text] [Related]